ArticleACS applied materials & interfaces2026
Nickel Single-Atom Nanozyme for Multimodal Cancer Therapy.
Article in ACS applied materials & interfaces, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nickel has recently emerged as a promising catalytic center for single-atom catalysts, owing to its biological relevance, redox versatility, and favorable coordination chemistry. Herein, we report the synthesis of a multifunctional nanozyme (Ni/PEG-FA) comprising atomically dispersed nickel sites anchored on a nitrogen-doped carbon support. The nanozyme is functionalized with poly(ethylene glycol) to improve colloidal stability and biocompatibility, and further conjugated with folic acid to enable the selective targeting of cancer cells overexpressing folate receptors. Ni/PEG-FA exhibits dual enzyme-mimicking activity, catalyzing both peroxidase-like and superoxide dismutase-like reactions for efficient reactive oxygen species generation under physiological conditions. In addition, Ni/PEG-FA shows strong photothermal conversion upon near-infrared laser irradiation, enabling effective thermal ablation of tumor cells. In vitro and in vivo evaluations demonstrate that Ni/PEG-FA elicits synergistic antitumor effects by combining catalytic oxidative stress with photothermal therapy, with minimal systemic toxicity. These findings underscore the potential of Ni-based single-atom nanozymes as a safe and effective platform for reactive oxygen species-powered cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.